Linesight’s life sciences benchmarking programme continues to grow, with five leading organisations joining the community between 2025 and 2026: Zoetis, Fujifilm, Novo Nordisk, Boehringer Ingelheim and Novartis.
Their participation further strengthens a programme built around collaboration, shared learning and industry insight. The addition of these organisations expands the breadth of experience within the community and reinforces the programme's position as a trusted forum for life sciences capital project professionals.
Linesight’s life sciences benchmarking programme brings together 27 organisations from across the global life sciences sector. Members contribute data, share experiences and exchange insights to help improve project outcomes across the sector.
More than a benchmarking initiative, the programme has become a highly engaged community. Members collaborate on the challenges shaping the future of life sciences facilities, from cost escalation and supply chain pressures to schedule certainty, sustainability and emerging delivery models.
By combining benchmarking data with peer-to-peer engagement, participants gain valuable insight into how projects are performing across the market and where opportunities exist to improve.
The programme provides members with access to benchmarking intelligence across a range of project types and capital investment programmes. Member data is securely managed, anonymised and aggregated before insights are shared, protecting confidentiality while enabling meaningful comparisons. This helps organisations:
As investment across the life sciences market continues to evolve, access to reliable data and trusted industry perspectives has never been more important.
To learn more about our Life Sciences Benchmarking Program and how your organization can benefit from participating, click here, or visit our team at booth #1102 during the ISPE Annual Meeting & Expo in the Washington, DC area from October 18–21, 2026.
Delegates interested in learning more about Linesight’s Life Sciences Benchmarking Programme will have the opportunity to meet our team at the International Society for Pharmaceutical Engineering (ISPE) Annual Meeting & Expo in Washington, DC from 19 to 21 October.
Visit us at booth #1102 to learn how the programme is helping organisations benchmark performance, identify trends and strengthen delivery outcomes across the life sciences construction industry.
Our team will be available throughout the event to discuss the latest benchmarking insights, emerging market trends and opportunities to become part of this growing community.
Amgen, AstraZeneca, Bayer, BD, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Catalent, Charles River Laboratories, CSL, Fujifilm, GSK, Johnson & Johnson, Kite Pharma, Lonza, Merck, MSD, Novartis, Novo Nordisk, Organon, Pfizer, Roche, Takeda, Thermo Fisher Scientific, UCB, WuXi Biologics, Zoetis.
Linesight is a global construction consultancy with over 50 years of experience, delivering cost, schedule, programme and project management services across data centres, life sciences, commercial, high tech industrial, residential, hospitality, healthcare and retail sectors.
We act as a strategic partner, combining global scale with local expertise to bring clarity, consistency and confidence to complex projects. Trusted by leading organisations, we build long term relationships grounded in transparency, accountability and shared outcomes.
Our work provides cost certainty and schedule confidence, enabling informed decisions from early planning through to completion.